Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library
- 17 November 2008
- journal article
- research article
- Published by Wiley in Biopolymers
- Vol. 91 (3) , 201-206
Abstract
We report here, the design and synthesis of a positional scanning synthetic combinatorial library for the identification of novel peptide ligands targeted against the cancer‐specific epidermal growth factor tyrosine kinase receptor mutation variant III (EGFRvIII). This receptor is expressed in several kinds of cancer, in particular, ovarian, glioblastomas, and breast cancer, but not in normal tissue. The library consisted of six individual positional sublibraries in the format, H‐O1–6XXXXX‐NH2, O being one of the 19 proteinogenic amino acids (cysteine omitted) and X an equimolar mixture of these. The library consisted of 114 mixtures in total. Using a biotin‐streptavidin assay, the binding of each sublibrary to NR6M, NR6W‐A, and NR6 cells was tested. These cells express EGFRvIII, EGFR, and neither of the receptors, respectively. The result from each sublibrary was examined to identify the most active amino acid residue at each position. On the basis of this knowledge, eight peptides were synthesized and tested for binding to EGFRvIII. We identified one peptide, H‐FALGEA‐NH2, that showed more selective binding to the mutated receptor than the EGFRvIII specific peptide PEPHC1. This study demonstrates the value of using mixture‐based combinatorial positional scanning libraries for the identification of novel peptide ligands targeted against the cancer‐specific EGFRvIII. Our best candidate H‐FALGEA‐NH2 will be radioactively labeled and evaluated as an imaging agent for positron emission tomography investigation for diagnosis, staging, and monitoring of therapy of various types of cancer. © 2008 Wiley Periodicals, Inc. Biopolymers 91: 201–206, 2009.This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.comKeywords
This publication has 25 references indexed in Scilit:
- Discovering and improving novel peptide therapeuticsCurrent Opinion in Pharmacology, 2008
- Identification of Amino Acid Residues in PEPHC1 Important for Binding to the Tumor‐Specific Receptor EGFRvIIIChemical Biology & Drug Design, 2008
- Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancerCancer Treatment Reviews, 2008
- Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal AntibodiesClinical Cancer Research, 2008
- A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIIIMolecular Cancer, 2007
- Production of a Novel Camel Single-Domain Antibody Specificfor the Type III Mutant EGFRTumor Biology, 2004
- Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapyInternational Journal of Cancer, 2003
- Design of a Novel Small Peptide Targeted against a Tumor-Specific ReceptorBiochemical and Biophysical Research Communications, 2000
- The “One-Bead-One-Compound” Combinatorial Library MethodChemical Reviews, 1997
- Ligand-Induced Transformation by a Noninternalizing Epidermal Growth Factor ReceptorScience, 1990